Synthesis and anticonvulsant activity of enaminones. 4. Investigations on isoxazole derivatives.

Due to the exceptional anticonvulsant activity displayed by substituted aniline enaminones, related pyridine derivatives and phenothiazines synthesised in our laboratories, the further investigation of various aromatic heterocycles was undertaken. Condensation of cyclic 1,3-diketo esters with 3-, and 5-aminoisoxazole derivatives led to a series of potent anti-maximal electroshock (MES) analogues, three of which occurred in the 3-amino series: ethyl ester (10), orally (po) active in rats [ED(50) 68.9 mg kg(-1), TD(50) > 500 mg kg(-1), protective index (PI = TD(50)/ED(50)) > 49.6]; methyl ester (9), ED(50) 68.9 mg kg(-1) intraperitoneally (ip) in mice, TD(50) > 500 mg kg(-1), PI > 7.3, and tert-butyl ester (8), ED(50) 28.1 mg kg(-1) po in rats, TD(50) > 500 mg kg(-1), PI > 17.8. Sodium channel binding studies, as well as evaluations against pentylenetetrazol, bicuculline, and picrotoxin on isoxazole 10 were all negative, leading to an unknown mechanism of action. X-ray diffraction patterns of a representative of the 3-amino series (isoxazoles 6-11) unequivocally display the existence of intramolecular hydrogen bonding of the nitrogen to the vinylic proton in the cyclohexene ring, providing a pseudo three ring structure which was also shown previously with the vinylic benzamides. Physicochemical-permeability across the BBB suggested an efflux mechanism for the previously synthesised aniline enaminones, but not with isoxazole 10.

[1]  E. A. Swinyard,et al.  Effect of stimulus intensity on the profile of anticonvulsant activity of phenytoin, ethosuximide and valproate. , 1985, The Journal of pharmacology and experimental therapeutics.

[2]  M. Mizugaki,et al.  Isoxazole derivatives as centrally acting muscle relaxants. II. Synthesis and structure-activity relationship of 3-amino-N-(3-phenyl-5-isoxazolyl)propanamides. , 1986, Chemical & pharmaceutical bulletin.

[3]  E. Lothman,et al.  Closely spaced recurrent hippocampal seizures elicit two types of heightened epileptogenesis: a rapidly developing, transient kindling and a slowly developing, enduring kindling , 1994, Brain Research.

[4]  K. Audus,et al.  Characterization of an In Vitro Blood–Brain Barrier Model System for Studying Drug Transport and Metabolism , 1986, Pharmaceutical Research.

[5]  A. Leo,et al.  Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. , 1987, Journal of pharmaceutical sciences.

[6]  W. Yonekawa,et al.  Potassium, Pentylenetetrazol, and Anticonvulsants in Mouse Hippocampal Slices , 1985, Epilepsia.

[7]  G. Cuvier,et al.  New N-aryl isoxazolecarboxamides and N-isoxazolylbenzamides as anticonvulsant agents , 1992 .

[8]  D. Scherman,et al.  Biology and Physiology of the Blood-Brain Barrier , 1996, Advances in Behavioral Biology.

[9]  R. Butcher,et al.  Synthesis, characterization and anticonvulsant activity of enaminones. Part 6: Synthesis of substituted vinylic benzamides as potential anticonvulsants. , 1999, Bioorganic & medicinal chemistry.

[10]  Philip L. Smith,et al.  In vitro models to predict blood-brain barrier permeability , 1997 .

[11]  B. G. White,et al.  Antiepileptic Drug Development Program. , 1984, Cleveland Clinic quarterly.

[12]  K R Scott,et al.  Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anticonvulsants. , 2001, Journal of pharmaceutical sciences.

[13]  J. Moore,et al.  Synthesis and anticonvulsant activity of enaminones. , 1992, Journal of medicinal chemistry.

[14]  R T Borchardt,et al.  Bovine Brain Microvessel Endothelial Cell Monolayers as a Model System for the Blood‐Brain Barrier a , 1987, Annals of the New York Academy of Sciences.

[15]  G. Rankin,et al.  Synthesis and anticonvulsant activity of enaminones. 3. Investigations on 4'-, 3'-, and 2'-substituted and polysubstituted anilino compounds, sodium channel binding studies, and toxicity evaluations. , 1995, Journal of medicinal chemistry.

[16]  J. Stables,et al.  Enaminones-versatile therapeutic pharmacophores. Further advances. , 2000, Current medicinal chemistry.

[17]  J. Daly,et al.  Batrachotoxin-induced depolarization and [3H]batrachotoxinin-a 20 alpha-benzoate binding in a vesicular preparation from guinea pig cerebral cortex. , 1983, Molecular pharmacology.

[18]  K. Audus,et al.  The Application of Bovine Brain Microvessel Endothelial-Cell Monolayers Grown onto Polycarbonate Membranes in Vitro to Estimate the Potential Permeability of Solutes Through the Blood–Brain Barrier , 1989, Pharmaceutical Research.

[19]  J. Penry,et al.  Antiepileptic Drug Development: II. Anticonvulsant Drug Screening , 1978, Epilepsia.

[20]  W. Catterall,et al.  Neurotoxin binding and allosteric modulation at receptor sites 2 and 5 on purified and reconstituted rat brain sodium channels. , 1993, The Journal of biological chemistry.

[21]  R. Butcher,et al.  Synthesis, characterization, and anticonvulsant activity of enaminones. Part 5: investigations on 3-carboalkoxy-2-methyl-2,3-dihydro-1H-phenothizin-4[10H]-one derivatives. , 1998, Bioorganic & medicinal chemistry.

[22]  R. Wyatt,et al.  The Hippocampal Slice: A System for Studying the Pharmacology of Seizures and for Screening Anticonvulsant Drugs , 1977, Epilepsia.

[23]  R. Racine,et al.  Modification of seizure activity by electrical stimulation. II. Motor seizure. , 1972, Electroencephalography and clinical neurophysiology.

[24]  W. Pardridge Transport of small molecules through the blood-brain barrier: biology and methodology. , 1995, Advanced drug delivery reviews.

[25]  J. Moore,et al.  Nuclear magnetic resonance studies of anticonvulsant enaminones. , 1994, Journal of pharmaceutical sciences.

[26]  A. El-Assadi,et al.  Synthesis and anticonvulsant activity of enaminones. 2. Further structure-activity correlations. , 1993, Journal of medicinal chemistry.